GlassScriptPhysician profile
Brett M Victor
NPI 1285897173
$41,264.59
in general payments reported to CMS, 2019-2025
21 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.46 · 2020: $23.72 · 2021: $148 · 2022: $526 · 2023: $275 · 2024: $553 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $2,122 · Travel and Lodging: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,541.25 |
| Food and Beverage | $2,122.23 |
| Travel and Lodging | $1,869.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39,429.76 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $357.33 | 2020-2024 | Xarelto |
| Atricure, INC. | $228.03 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $190.22 | 2022 | |
| Amgen INC. | $184.07 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.60 | 2024-2025 | Jardiance |
| Endotronix, INC. | $126.57 | 2022 | |
| Bridgebio Pharma, INC. | $112.15 | 2025 | Attruby |
| Infobionic, INC | $105.82 | 2023 | Mome Kardia |
| Esperion Therapeutics, INC. | $60.32 | 2024-2025 | Nexletol |
| Siemens Medical Solutions USA, INC. | $50.08 | 2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Medtronic, INC. | $49.90 | 2025 | Closurefast |
| Astrazeneca Pharmaceuticals LP | $41.18 | 2024-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $37.44 | 2021-2025 | Eliquis |
| Bard Peripheral Vascular, INC. | $34.46 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $26.07 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $24.90 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.39 | 2025 | Onpattro |
| Heartflow, INC. | $21.48 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.65 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $10.17 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Victor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.